JP2009525297A - コンディショニング済み血液組成物およびその製造方法 - Google Patents
コンディショニング済み血液組成物およびその製造方法 Download PDFInfo
- Publication number
- JP2009525297A JP2009525297A JP2008552751A JP2008552751A JP2009525297A JP 2009525297 A JP2009525297 A JP 2009525297A JP 2008552751 A JP2008552751 A JP 2008552751A JP 2008552751 A JP2008552751 A JP 2008552751A JP 2009525297 A JP2009525297 A JP 2009525297A
- Authority
- JP
- Japan
- Prior art keywords
- blood
- blood composition
- interleukin
- muscle
- container
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 210000004369 blood Anatomy 0.000 title claims abstract description 199
- 239000008280 blood Substances 0.000 title claims abstract description 199
- 239000000203 mixture Substances 0.000 title claims abstract description 143
- 230000001143 conditioned effect Effects 0.000 title claims abstract description 79
- 238000004519 manufacturing process Methods 0.000 title claims description 11
- 238000000034 method Methods 0.000 claims abstract description 41
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 29
- 201000010099 disease Diseases 0.000 claims abstract description 27
- 241001465754 Metazoa Species 0.000 claims abstract description 25
- 102000004889 Interleukin-6 Human genes 0.000 claims abstract description 19
- 108090001005 Interleukin-6 Proteins 0.000 claims abstract description 19
- 229940100601 interleukin-6 Drugs 0.000 claims abstract description 19
- 210000002966 serum Anatomy 0.000 claims description 35
- 238000011282 treatment Methods 0.000 claims description 28
- 238000011534 incubation Methods 0.000 claims description 22
- 101001076407 Homo sapiens Interleukin-1 receptor antagonist protein Proteins 0.000 claims description 16
- 229940119178 Interleukin 1 receptor antagonist Drugs 0.000 claims description 16
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 claims description 16
- 239000003407 interleukin 1 receptor blocking agent Substances 0.000 claims description 16
- 210000002435 tendon Anatomy 0.000 claims description 15
- 102000004388 Interleukin-4 Human genes 0.000 claims description 12
- 108090000978 Interleukin-4 Proteins 0.000 claims description 12
- 229940028885 interleukin-4 Drugs 0.000 claims description 12
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims description 11
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims description 11
- 102000000589 Interleukin-1 Human genes 0.000 claims description 11
- 108010002352 Interleukin-1 Proteins 0.000 claims description 11
- 102000003814 Interleukin-10 Human genes 0.000 claims description 11
- 108090000174 Interleukin-10 Proteins 0.000 claims description 11
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 11
- 230000001684 chronic effect Effects 0.000 claims description 11
- 229940126864 fibroblast growth factor Drugs 0.000 claims description 11
- 229940076144 interleukin-10 Drugs 0.000 claims description 11
- 102000003390 tumor necrosis factor Human genes 0.000 claims description 11
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 claims description 10
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 claims description 10
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 10
- 102000014429 Insulin-like growth factor Human genes 0.000 claims description 10
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 claims description 10
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 claims description 10
- 102000009618 Transforming Growth Factors Human genes 0.000 claims description 10
- 108010009583 Transforming Growth Factors Proteins 0.000 claims description 10
- 206010061218 Inflammation Diseases 0.000 claims description 9
- 102000003816 Interleukin-13 Human genes 0.000 claims description 9
- 108090000176 Interleukin-13 Proteins 0.000 claims description 9
- 201000009053 Neurodermatitis Diseases 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- 230000004054 inflammatory process Effects 0.000 claims description 9
- 201000009273 Endometriosis Diseases 0.000 claims description 8
- 241001420836 Ophthalmitis Species 0.000 claims description 8
- 208000010403 panophthalmitis Diseases 0.000 claims description 8
- -1 polyethylene Polymers 0.000 claims description 8
- 208000029578 Muscle disease Diseases 0.000 claims description 7
- 208000029549 Muscle injury Diseases 0.000 claims description 7
- 208000027418 Wounds and injury Diseases 0.000 claims description 7
- 230000001413 cellular effect Effects 0.000 claims description 7
- 206010052428 Wound Diseases 0.000 claims description 6
- 230000006698 induction Effects 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 6
- 210000003205 muscle Anatomy 0.000 claims description 6
- 241000283086 Equidae Species 0.000 claims description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 5
- 239000000835 fiber Substances 0.000 claims description 5
- 239000011521 glass Substances 0.000 claims description 5
- 210000000987 immune system Anatomy 0.000 claims description 5
- 230000007794 irritation Effects 0.000 claims description 5
- 210000000056 organ Anatomy 0.000 claims description 5
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- 239000001301 oxygen Substances 0.000 claims description 5
- 206010028289 Muscle atrophy Diseases 0.000 claims description 4
- 230000006806 disease prevention Effects 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 210000000653 nervous system Anatomy 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 206010020751 Hypersensitivity Diseases 0.000 claims description 3
- 230000007815 allergy Effects 0.000 claims description 3
- 239000002537 cosmetic Substances 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 210000001808 exosome Anatomy 0.000 claims description 3
- 206010056340 Diabetic ulcer Diseases 0.000 claims description 2
- 206010049565 Muscle fatigue Diseases 0.000 claims description 2
- 206010070521 Muscle hernia Diseases 0.000 claims description 2
- 208000000112 Myalgia Diseases 0.000 claims description 2
- 239000004698 Polyethylene Substances 0.000 claims description 2
- 239000004743 Polypropylene Substances 0.000 claims description 2
- 239000004793 Polystyrene Substances 0.000 claims description 2
- 229910000831 Steel Inorganic materials 0.000 claims description 2
- 230000000735 allogeneic effect Effects 0.000 claims description 2
- 239000011805 ball Substances 0.000 claims description 2
- 229910052751 metal Inorganic materials 0.000 claims description 2
- 239000002184 metal Substances 0.000 claims description 2
- 229910044991 metal oxide Inorganic materials 0.000 claims description 2
- 150000004706 metal oxides Chemical class 0.000 claims description 2
- 150000002739 metals Chemical class 0.000 claims description 2
- 230000020763 muscle atrophy Effects 0.000 claims description 2
- 208000013465 muscle pain Diseases 0.000 claims description 2
- 201000000585 muscular atrophy Diseases 0.000 claims description 2
- 201000006938 muscular dystrophy Diseases 0.000 claims description 2
- 210000001087 myotubule Anatomy 0.000 claims description 2
- 239000004033 plastic Substances 0.000 claims description 2
- 229920003023 plastic Polymers 0.000 claims description 2
- 229920000573 polyethylene Polymers 0.000 claims description 2
- 229920001155 polypropylene Polymers 0.000 claims description 2
- 229920002223 polystyrene Polymers 0.000 claims description 2
- 239000004800 polyvinyl chloride Substances 0.000 claims description 2
- 229920000915 polyvinyl chloride Polymers 0.000 claims description 2
- 239000010453 quartz Substances 0.000 claims description 2
- 230000008929 regeneration Effects 0.000 claims description 2
- 238000011069 regeneration method Methods 0.000 claims description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 2
- 239000010959 steel Substances 0.000 claims description 2
- 238000001356 surgical procedure Methods 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 230000006735 deficit Effects 0.000 claims 1
- 230000035699 permeability Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229940124531 pharmaceutical excipient Drugs 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 abstract description 26
- 108090000695 Cytokines Proteins 0.000 abstract description 26
- 230000002265 prevention Effects 0.000 abstract description 8
- 208000002193 Pain Diseases 0.000 description 16
- 239000012503 blood component Substances 0.000 description 16
- 239000000306 component Substances 0.000 description 15
- QXJJQWWVWRCVQT-UHFFFAOYSA-K calcium;sodium;phosphate Chemical compound [Na+].[Ca+2].[O-]P([O-])([O-])=O QXJJQWWVWRCVQT-UHFFFAOYSA-K 0.000 description 11
- 239000007924 injection Substances 0.000 description 11
- 238000002347 injection Methods 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 9
- 238000005119 centrifugation Methods 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 241000283073 Equus caballus Species 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 239000005388 borosilicate glass Substances 0.000 description 6
- 238000011049 filling Methods 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 208000030175 lameness Diseases 0.000 description 5
- 206010018852 Haematoma Diseases 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- XMTQQYYKAHVGBJ-UHFFFAOYSA-N 3-(3,4-DICHLOROPHENYL)-1,1-DIMETHYLUREA Chemical compound CN(C)C(=O)NC1=CC=C(Cl)C(Cl)=C1 XMTQQYYKAHVGBJ-UHFFFAOYSA-N 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 208000008035 Back Pain Diseases 0.000 description 3
- 206010018910 Haemolysis Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 229940035676 analgesics Drugs 0.000 description 3
- 239000000730 antalgic agent Substances 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000005786 degenerative changes Effects 0.000 description 3
- 239000005293 duran Substances 0.000 description 3
- 239000003862 glucocorticoid Substances 0.000 description 3
- 230000008588 hemolysis Effects 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 230000007704 transition Effects 0.000 description 3
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 2
- 208000000094 Chronic Pain Diseases 0.000 description 2
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 2
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 2
- 241001215120 Leptospirales Species 0.000 description 2
- 208000023178 Musculoskeletal disease Diseases 0.000 description 2
- 208000021945 Tendon injury Diseases 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 229960004544 cortisone Drugs 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000001503 joint Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 229940037128 systemic glucocorticoids Drugs 0.000 description 2
- 229960005294 triamcinolone Drugs 0.000 description 2
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000036487 Arthropathies Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010061819 Disease recurrence Diseases 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 241000589902 Leptospira Species 0.000 description 1
- 206010061223 Ligament injury Diseases 0.000 description 1
- 206010070757 Muscle contusion Diseases 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 108700012920 TNF Proteins 0.000 description 1
- 208000000491 Tendinopathy Diseases 0.000 description 1
- 206010043255 Tendonitis Diseases 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- GRWVQDDAKZFPFI-UHFFFAOYSA-H chromium(III) sulfate Chemical compound [Cr+3].[Cr+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GRWVQDDAKZFPFI-UHFFFAOYSA-H 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 210000000003 hoof Anatomy 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 201000004614 iritis Diseases 0.000 description 1
- 208000024765 knee pain Diseases 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000005499 meniscus Effects 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 210000002487 multivesicular body Anatomy 0.000 description 1
- POFWRMVFWIJXHP-UHFFFAOYSA-N n-benzyl-9-(oxan-2-yl)purin-6-amine Chemical compound C=1C=CC=CC=1CNC(C=1N=C2)=NC=NC=1N2C1CCCCO1 POFWRMVFWIJXHP-UHFFFAOYSA-N 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 201000004415 tendinitis Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003634 thrombocyte concentrate Substances 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2006—IL-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2026—IL-4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/204—IL-6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2066—IL-10
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2086—IL-13 to IL-16
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/02—Blood transfusion apparatus
- A61M1/0209—Multiple bag systems for separating or storing blood components
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Wood Science & Technology (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Plant Pathology (AREA)
- Cell Biology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102006005016A DE102006005016A1 (de) | 2006-02-03 | 2006-02-03 | Konditionierte Blutzusammensetzung und Verfahren zu deren Herstellung |
| PCT/EP2007/000903 WO2007090569A1 (de) | 2006-02-03 | 2007-02-02 | Konditionierte blutzusammensetzung und verfahren zu deren herstellung |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009525297A true JP2009525297A (ja) | 2009-07-09 |
| JP2009525297A5 JP2009525297A5 (https=) | 2010-03-11 |
Family
ID=37965046
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008552751A Withdrawn JP2009525297A (ja) | 2006-02-03 | 2007-02-02 | コンディショニング済み血液組成物およびその製造方法 |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20090047242A1 (https=) |
| EP (2) | EP1984006B1 (https=) |
| JP (1) | JP2009525297A (https=) |
| KR (1) | KR20080100425A (https=) |
| CN (1) | CN101378768A (https=) |
| AT (1) | ATE446100T1 (https=) |
| AU (1) | AU2007213996A1 (https=) |
| BR (1) | BRPI0707360A2 (https=) |
| CA (1) | CA2640002A1 (https=) |
| CY (1) | CY1109735T1 (https=) |
| DE (2) | DE102006005016A1 (https=) |
| DK (1) | DK1984006T3 (https=) |
| EA (1) | EA014435B1 (https=) |
| ES (1) | ES2335446T3 (https=) |
| HR (1) | HRP20090684T1 (https=) |
| MX (1) | MX2008009807A (https=) |
| PL (1) | PL1984006T3 (https=) |
| PT (1) | PT1984006E (https=) |
| RS (1) | RS51247B (https=) |
| SI (1) | SI1984006T1 (https=) |
| UA (1) | UA90048C2 (https=) |
| WO (1) | WO2007090569A1 (https=) |
| ZA (1) | ZA200805975B (https=) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013504542A (ja) * | 2009-09-10 | 2013-02-07 | フレミング・ヴェリン | マイクロｒｎａの製造方法およびその治療的応用 |
| JP7624256B1 (ja) | 2024-01-26 | 2025-01-30 | 万里 坂井 | 医薬組成物及びその製造方法 |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7832566B2 (en) | 2002-05-24 | 2010-11-16 | Biomet Biologics, Llc | Method and apparatus for separating and concentrating a component from a multi-component material including macroparticles |
| US20060278588A1 (en) | 2002-05-24 | 2006-12-14 | Woodell-May Jennifer E | Apparatus and method for separating and concentrating fluids containing multiple components |
| US8034014B2 (en) | 2007-03-06 | 2011-10-11 | Biomet Biologics, Llc | Angiogenesis initation and growth |
| US20080269762A1 (en) * | 2007-04-25 | 2008-10-30 | Biomet Manufacturing Corp. | Method and device for repair of cartilage defects |
| US8753690B2 (en) * | 2008-02-27 | 2014-06-17 | Biomet Biologics, Llc | Methods and compositions for delivering interleukin-1 receptor antagonist |
| EP2567692B1 (en) | 2008-02-27 | 2016-04-06 | Biomet Biologics, LLC | Use of a device for obtaining interleukin-1 receptor antagonist rich solutions |
| DE102008028684A1 (de) * | 2008-06-17 | 2009-12-24 | Kopetzky, Robert, Dr. | Blutbeutel |
| US8460227B2 (en) | 2008-11-17 | 2013-06-11 | Arthrex, Inc. | Cytokine concentration system |
| CA2757517A1 (en) | 2009-04-07 | 2010-10-21 | Velin-Pharma A/S | Method and device for treatment of conditions associated with inflammation or undesirable activation of the immune system |
| US20110052561A1 (en) * | 2009-08-27 | 2011-03-03 | Biomet Biologics,LLC | Osteolysis treatment |
| US9763875B2 (en) | 2009-08-27 | 2017-09-19 | Biomet Biologics, Llc | Implantable device for production of interleukin-1 receptor antagonist |
| DE202009017772U1 (de) | 2009-12-10 | 2011-04-21 | Orthogen Ag | Kombinationspräparate mit Cytokin-Antagonist und Corticosteroid |
| AU2011296356B2 (en) | 2010-09-03 | 2015-07-09 | Biomet Biologics, Llc | Methods and compositions for delivering interleukin-1 receptor antagonist |
| DE102010042356A1 (de) * | 2010-10-12 | 2012-04-12 | Henke-Sass, Wolf Gmbh | Behälter für die Herstellung einer konditionierten Blutzusammensetzung |
| US9011846B2 (en) | 2011-05-02 | 2015-04-21 | Biomet Biologics, Llc | Thrombin isolated from blood and blood fractions |
| US9205110B2 (en) | 2012-07-18 | 2015-12-08 | Arthrex, Inc. | Enhanced autologous growth factor production and delivery system |
| DE102012019088A1 (de) * | 2012-09-28 | 2014-04-03 | Orthogen Ag | Antibakterielle Arzneimittelpräparate |
| CA2900971C (en) | 2013-02-12 | 2023-08-08 | Lacerta Technologies Inc. | Serum fraction of platelet-rich fibrin |
| US9758806B2 (en) | 2013-03-15 | 2017-09-12 | Biomet Biologics, Llc | Acellular compositions for treating inflammatory disorders |
| US20140271589A1 (en) | 2013-03-15 | 2014-09-18 | Biomet Biologics, Llc | Treatment of collagen defects using protein solutions |
| US9878011B2 (en) | 2013-03-15 | 2018-01-30 | Biomet Biologics, Llc | Treatment of inflammatory respiratory disease using biological solutions |
| US9950035B2 (en) | 2013-03-15 | 2018-04-24 | Biomet Biologics, Llc | Methods and non-immunogenic compositions for treating inflammatory disorders |
| US10208095B2 (en) | 2013-03-15 | 2019-02-19 | Biomet Manufacturing, Llc | Methods for making cytokine compositions from tissues using non-centrifugal methods |
| US10143725B2 (en) | 2013-03-15 | 2018-12-04 | Biomet Biologics, Llc | Treatment of pain using protein solutions |
| US9895418B2 (en) | 2013-03-15 | 2018-02-20 | Biomet Biologics, Llc | Treatment of peripheral vascular disease using protein solutions |
| EP2829278A1 (de) * | 2013-07-23 | 2015-01-28 | Scientific BioTech GmbH | Serum zur Behnandlung von Krankheiten |
| US9833474B2 (en) | 2013-11-26 | 2017-12-05 | Biomet Biologies, LLC | Methods of mediating macrophage phenotypes |
| WO2015085348A1 (en) * | 2013-12-09 | 2015-06-18 | Cytokine Medical Australia Pty Ltd | Apparatus for producing therapeutically active proteins in blood and uses thereof |
| US10441635B2 (en) | 2014-11-10 | 2019-10-15 | Biomet Biologics, Llc | Methods of treating pain using protein solutions |
| US9763800B2 (en) | 2015-03-18 | 2017-09-19 | Biomet C. V. | Implant configured for hammertoe and small bone fixation |
| EA201890841A1 (ru) * | 2016-08-17 | 2018-09-28 | Ортоген Аг | Фармацевтический препарат против старения |
| EP3613424A1 (en) | 2018-08-23 | 2020-02-26 | Orthogen AG | Novel methods for the production of pharmaceutical agents |
| DE102021124752A1 (de) | 2021-09-24 | 2023-03-30 | Ad Lentus GmbH | Autologes Therapeutikum und Verfahren zur Herstellung desselben |
| CN114146096B (zh) * | 2021-11-25 | 2024-04-02 | 成都清科生物科技有限公司 | 一种富含细胞因子的条件血清的制备方法及应用 |
| WO2024237773A1 (ru) * | 2023-05-15 | 2024-11-21 | Роман ЮХТ | Способ получения кондиционированной композиции крови для лечения заболеваний |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4244437A1 (de) * | 1992-12-29 | 1994-07-28 | Horst Dr Med Kief | Verfahren zur Gewinnung körpereigener Zytokine |
| DE19903876B4 (de) * | 1999-02-01 | 2006-09-28 | Orthogen Gentechnologie Gmbh | Verfahren zur in-vitro-Bildung und Anreicherung von Interleukin-1 Rezeptor-Antagonisten |
| US20020081324A1 (en) * | 2002-01-22 | 2002-06-27 | Twine Rebecca Wright | Method of treating aging skin and wrinkles using a combination of growth factors that is commercially prepared or derived from one's own blood |
-
2006
- 2006-02-03 DE DE102006005016A patent/DE102006005016A1/de not_active Withdrawn
-
2007
- 2007-02-02 HR HR20090684T patent/HRP20090684T1/hr unknown
- 2007-02-02 ES ES07711428T patent/ES2335446T3/es active Active
- 2007-02-02 JP JP2008552751A patent/JP2009525297A/ja not_active Withdrawn
- 2007-02-02 CN CNA2007800044614A patent/CN101378768A/zh active Pending
- 2007-02-02 EP EP07711428A patent/EP1984006B1/de not_active Revoked
- 2007-02-02 EP EP09013177A patent/EP2156841A1/de not_active Withdrawn
- 2007-02-02 SI SI200730130T patent/SI1984006T1/sl unknown
- 2007-02-02 BR BRPI0707360-7A patent/BRPI0707360A2/pt not_active IP Right Cessation
- 2007-02-02 PT PT07711428T patent/PT1984006E/pt unknown
- 2007-02-02 US US12/162,022 patent/US20090047242A1/en not_active Abandoned
- 2007-02-02 DK DK07711428.8T patent/DK1984006T3/da active
- 2007-02-02 CA CA002640002A patent/CA2640002A1/en not_active Abandoned
- 2007-02-02 MX MX2008009807A patent/MX2008009807A/es not_active Application Discontinuation
- 2007-02-02 AU AU2007213996A patent/AU2007213996A1/en not_active Abandoned
- 2007-02-02 EA EA200870222A patent/EA014435B1/ru not_active IP Right Cessation
- 2007-02-02 ZA ZA200805975A patent/ZA200805975B/xx unknown
- 2007-02-02 PL PL07711428T patent/PL1984006T3/pl unknown
- 2007-02-02 DE DE502007001793T patent/DE502007001793D1/de active Active
- 2007-02-02 WO PCT/EP2007/000903 patent/WO2007090569A1/de not_active Ceased
- 2007-02-02 UA UAA200810851A patent/UA90048C2/ru unknown
- 2007-02-02 RS RSP-2010/0012A patent/RS51247B/sr unknown
- 2007-02-02 KR KR1020087018622A patent/KR20080100425A/ko not_active Ceased
- 2007-02-02 AT AT07711428T patent/ATE446100T1/de active
-
2010
- 2010-01-15 CY CY20101100046T patent/CY1109735T1/el unknown
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013504542A (ja) * | 2009-09-10 | 2013-02-07 | フレミング・ヴェリン | マイクロｒｎａの製造方法およびその治療的応用 |
| JP7624256B1 (ja) | 2024-01-26 | 2025-01-30 | 万里 坂井 | 医薬組成物及びその製造方法 |
| WO2025159140A1 (ja) * | 2024-01-26 | 2025-07-31 | 万里 坂井 | 医薬組成物及びその製造方法 |
| JP2025115573A (ja) * | 2024-01-26 | 2025-08-07 | 万里 坂井 | 医薬組成物及びその製造方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20090047242A1 (en) | 2009-02-19 |
| RS51247B (sr) | 2010-12-31 |
| WO2007090569A8 (de) | 2008-02-28 |
| CN101378768A (zh) | 2009-03-04 |
| CA2640002A1 (en) | 2007-08-16 |
| HRP20090684T1 (hr) | 2010-02-28 |
| KR20080100425A (ko) | 2008-11-18 |
| EP1984006A1 (de) | 2008-10-29 |
| EA200870222A1 (ru) | 2008-12-30 |
| EP1984006B1 (de) | 2009-10-21 |
| PL1984006T3 (pl) | 2010-03-31 |
| ZA200805975B (en) | 2010-08-25 |
| WO2007090569A1 (de) | 2007-08-16 |
| DE502007001793D1 (de) | 2009-12-03 |
| BRPI0707360A2 (pt) | 2011-05-03 |
| PT1984006E (pt) | 2010-01-20 |
| DK1984006T3 (da) | 2010-03-01 |
| CY1109735T1 (el) | 2014-09-10 |
| UA90048C2 (ru) | 2010-03-25 |
| EA014435B1 (ru) | 2010-12-30 |
| ATE446100T1 (de) | 2009-11-15 |
| HK1125835A1 (zh) | 2009-08-21 |
| SI1984006T1 (sl) | 2010-02-26 |
| DE102006005016A1 (de) | 2007-08-16 |
| ES2335446T3 (es) | 2010-03-26 |
| EP2156841A1 (de) | 2010-02-24 |
| MX2008009807A (es) | 2008-09-26 |
| AU2007213996A1 (en) | 2007-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009525297A (ja) | コンディショニング済み血液組成物およびその製造方法 | |
| Barba et al. | Intratumoral LAK cell and interleukin-2 therapy of human gliomas | |
| EP2361972B1 (en) | Stem cells derived from bone marrow for tissue regeneration | |
| JP2009525297A5 (https=) | ||
| US10993969B2 (en) | Methods and materials for treating nerve injuries and neurological disorders | |
| CN117241807A (zh) | 小体积卒中的细胞疗法和治疗方法 | |
| CN109562145B (zh) | 含胰岛素样生长因子-2的药物组合物及其应用 | |
| Sterz et al. | Effects of U74006F on multifocal cerebral blood flow and metabolism after cardiac arrest in dogs. | |
| TWI902336B (zh) | 二價金屬乳酸鹽在製備修復神經損傷之製品中的用途 | |
| CN107412264A (zh) | 用于治疗男性勃起障碍的药物及其制备和使用方法 | |
| CN117899006A (zh) | 一种负载双硫仑纳米囊泡的复合水凝胶及其在制备糖尿病皮肤创面愈合药物中的应用 | |
| Strauss | Neutrophil collection and transfusion | |
| RU2851115C1 (ru) | Способ лечения спондилоартроза с применением аутологичного тромбоцитарного концентрата и аутологичной плазмы крови | |
| CN112704687A (zh) | 含间充质干细胞的制剂及其在银屑病治疗中的应用 | |
| RU2808256C1 (ru) | Способ персонифицированной генной терапии при угрозе ишемического инсульта головного мозга | |
| Uhthoff et al. | A clinical study of quazepam in hospitalized patients with insomnia | |
| HK1125835B (en) | Conditioned blood composition and method for its production | |
| EU et al. | Our Mission | |
| CN106924815A (zh) | 用于整形充填的自体外周血干细胞和自体脂肪组合物 | |
| US20190321412A1 (en) | Methods and compositions using dehydrated human amnion/chorion membrane allograft and amnionic membrane allograft suspensions for the treatment of hair loss | |
| CN118987029A (zh) | 一种膝骨关节炎自血治疗方法 | |
| Sampson et al. | Clinical Aspects of Regenerative Medicine: Tendon, Ligament, and Joint | |
| WO2005097170A1 (ja) | 血管新生促進剤および血管新生療法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100122 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100122 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20101217 |